Literature DB >> 11928081

Coagulation disorders in liver disease.

Lucio Amitrano1, Maria A Guardascione, Vincenzo Brancaccio, Antonio Balzano.   

Abstract

The liver plays a central role in the clotting process, and acute and chronic liver diseases are invariably associated with coagulation disorders due to multiple causes: decreased synthesis of clotting and inhibitor factors, decreased clearance of activated factors, quantitative and qualitative platelet defects, hyperfibrinolysis, and accelerated intravascular coagulation. The bleeding tendency accounts for increased risk of morbidity and mortality in patients with liver disease undergoing diagnostic or therapeutic invasive procedures. Peculiar coagulation disorders are prevalent in patients with acute fatty liver of pregnancy or undergoing liver transplantation. Emerging evidence shows that sepsis further impairs hemostasis in patients with liver cirrhosis bleeding from esophageal varices. Thrombotic events, even if rare in cirrhotic patients, occur mainly in the portal and mesenteric veins. The therapeutic approach to coagulative disorders is also discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11928081     DOI: 10.1055/s-2002-23205

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  79 in total

Review 1.  Coagulation in sepsis.

Authors:  André Amaral; Steven M Opal; Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2004-05-18       Impact factor: 17.440

2.  Modelling Factors Causing Mortality in Oesophageal VaricesPatients in King Abdul Aziz University Hospital.

Authors:  Sami Bahlas
Journal:  Oman Med J       Date:  2009-07

Review 3.  Infection, coagulation, and variceal bleeding in cirrhosis.

Authors:  U Thalheimer; C K Triantos; D N Samonakis; D Patch; A K Burroughs
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

Review 4.  New insights into the coagulopathy of liver disease and liver transplantation.

Authors:  M Senzolo; P Burra; E Cholongitas; A-K Burroughs
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

5.  Evaluation of high-fat high-fructose diet treatment in factor VIII (coagulation factor)-deficient mouse model.

Authors:  Alaknanda Mishra; Shailendra Arindkar; Preeti Sahay; Jerald Mahesh Kumar; Pramod K Upadhyay; Subeer S Majumdar; Perumal Nagarajan
Journal:  Int J Exp Pathol       Date:  2018-04-15       Impact factor: 1.925

6.  Translational and transcriptional responses in human primary hepatocytes under hypoxia.

Authors:  Gaya K Hettiarachchi; Upendra K Katneni; Ryan C Hunt; Jacob M Kames; John C Athey; Haim Bar; Zuben E Sauna; Joseph R McGill; Juan C Ibla; Chava Kimchi-Sarfaty
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-03-28       Impact factor: 4.052

Review 7.  Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.

Authors:  Jochen Graff; Sebastian Harder
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

8.  Purpura fulminans in a newborn infant with galactosemia.

Authors:  Aysegul Zenciroglu; Mehmet Sah Ipek; Mustafa Aydin; Abdurrahman Kara; Nurullah Okumus; Mustafa Kilic
Journal:  Eur J Pediatr       Date:  2009-12-17       Impact factor: 3.183

9.  Pulmonary resection for non-small cell lung cancer in patients with hepatocellular carcinoma.

Authors:  Takashi Iwata; Noritoshi Nishiyama; Koshi Nagano; Nobuhiro Izumi; Shinjiro Mizuguchi; Ryuhei Morita; Takuma Tsukioka; Shoji Hanada; Kiyotoshi Inoue; Shoji Kubo; Shigekazu Takemura; Shigefumi Suehiro
Journal:  World J Surg       Date:  2008-10       Impact factor: 3.352

Review 10.  Spectrum of anemia associated with chronic liver disease.

Authors:  Rosario Gonzalez-Casas; E Anthony Jones; Ricardo Moreno-Otero
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.